Core Viewpoint - Hongyuan Pharmaceutical expects a significant increase in net profit for the fiscal year 2025, driven primarily by its lithium hexafluorophosphate business, which has seen improved profitability due to rising demand in the new energy vehicle and energy storage markets [1] Financial Performance - The projected net profit for 2025 is estimated to be between 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.20% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 82 million to 106 million yuan, showing a substantial year-on-year increase of 782.01% to 1,040.17% [1] - The impact of non-recurring gains and losses on the net profit attributable to shareholders of the listed company is estimated to be approximately 31 million yuan [1] Business Drivers - The significant growth in the company's operating performance is mainly attributed to the lithium hexafluorophosphate business [1] - Continuous growth in demand for new energy vehicles and rapid expansion in the energy storage market have contributed to the notable improvement in profitability [1]
宏源药业：预计2025年净利润同比增长119.57%～166.20%